There is no cure for type 1 diabetes (T1D). The immune system destroys the cells in the pancreas that make insulin, so most people need insulin every day to stay alive. One drug can now change the course of the disease: teplizumab (Tzield) can delay diagnosis in people in the early, symptom-free stage. Since June 12, 2026, in the U.S., it can also slow the loss of the body's own insulin in children 8 to 17 who were recently diagnosed. The closest thing to a cure is islet cell replacement. In a small trial, Vertex's lab-grown cells (zimislecel) let 10 of 12 people stop insulin, but everyone needs lifelong immune-suppressing drugs. Our view: a functional cure for some people looks reachable. A cure without immune suppression is still at the one-patient stage.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a diabetes care team.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your diabetes care team.
Could a blood test for exhausted-like T cells, taken a few months after teplizumab, show whose immune attack has quieted and whose has not (a test that does not yet exist for this use)? In a clinical trial, would adding a different, longer-running immune drug only for the second group keep more of their own insulin production than teplizumab alone? Insulin would still be needed throughout.
What would prove it wrong: if these T-cell signals do not predict who keeps their C-peptide, or if a response-guided second drug preserves no more C-peptide than teplizumab alone.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
Researchers studied 600 adults diagnosed within the past year in Germany, and checked the results in a second group of 483. They found three subtypes: two with islet antibodies (GADA-positive) and one without. One antibody-positive subtype, with higher body weight, lower insulin sensitivity and better beta-cell function, looked to be about 6 years earlier on the path of beta-cell loss than the classic subtype. The authors say this may point to a time window for treatments that slow the disease in some people. This is an observational study; no treatment was tested and it is not a cure.
In 111 adults with type 1 diabetes and overweight or obesity, a daily injection of acmopatide for 16 weeks lowered HbA1c by 0.4 to 0.6 points, compared with 0.3 on placebo. Only the middle dose (4.1 mg) was nominally better than placebo (0.3 points; P = 0.020). Body weight fell 3.3% to 6.7% (placebo: up 0.3%). Side effects were mostly stomach-related, with no diabetic ketoacidosis or severe low blood sugar. It is a short, mid-size Phase 2 trial run by the maker (Genentech), and it is not approved for type 1 diabetes. It helps manage the disease; it is not a cure.
In 72 children who had type 1 diabetes for at least 7 years, 22 (30.6%) still made a small amount of their own insulin. Those with a shorter time since diagnosis and a higher C-peptide level (a marker of insulin making) at diagnosis were more likely to keep it. Small single-study finding; it describes who keeps insulin production, not a treatment.
In 143 people with type 1 diabetes and HbA1c of 8% or higher, a smart injection system that prompts insulin doses was no worse than injections plus a continuous glucose monitor for time in range at 6 months (difference 0.19 percentage points) and not better. People who acted on more of the alerts did better in a later, not pre-planned analysis. This is about managing diabetes, not curing it.
A group of 22 experts from 13 U.S. medical centers, working with the T1D Exchange network, agreed on guidance for screening people at risk for type 1 diabetes with autoantibody tests and for using disease-modifying drugs such as teplizumab in stage 2 and newly diagnosed stage 3 disease. The authors say real-world guidance has been limited. It is expert consensus, not a new trial.
Among 4,299 people diagnosed with type 1 diabetes before age 35 (2000 to 2022) and 17,196 matched people without it, death rates were 131 versus 35 per 100,000 person-years, about 3.7 times higher. The extra risk was larger in women and lower for people diagnosed more recently (2011 to 2022). This is an observational study and does not show cause and effect.
A 44-year-old man with Down syndrome developed a severe immune reaction (HLH) linked to Epstein-Barr virus reactivation after a teplizumab course. He recovered with treatment. The authors say cause and effect can't be proven.
In 18 people in a Chinese trial, four infusions of gingiva-derived stem cells were safe and linked to better C-peptide (a sign of the body's own insulin) at 12 weeks, plus lower insulin doses. Very small and early.
The daily pill is the first new treatment approved in more than 30 years for kidney disease in adults with type 1 diabetes. In the 242-person FINE-ONE trial, a kidney-damage marker (UACR) was 22% lower than on placebo at 3 months and 28% lower at 6 months (company-reported). Overall side effects were similar to placebo, but high blood potassium was more common (10.1% vs 3.3%). It treats kidney disease, not diabetes itself.
Among 275 children and teens who took treatment as planned, teplizumab kept more C-peptide at 78 weeks, lowered insulin doses and slightly raised time in range compared with placebo.
Vertex said the trial "continues to enroll and dose patients" and that updated timelines for zimislecel and VX-017, a next cell therapy cleared for a Phase 1/2 trial, will come later in 2026. Dosing had been paused for a manufacturing review and resumed by May 2026.
A follow-up letter in NEJM reports that gene-edited donor islet cells in one person in Sweden kept working for 14 months with no immune-suppressing drugs.
Final guidance recommends teplizumab for people 8 and older with stage 2 T1D. NICE says England is the first country in Europe to recommend it through a health technology appraisal.
In 400 children and young adults in Bangladesh and Tanzania, switching to glargine did not change time in very low blood sugar or time in range at 6 months.
Accelerated approval to delay the decline of insulin production in ages 8 to 17 recently diagnosed with stage 3 T1D, based on C-peptide. A confirmatory study is needed.
In 220 children with stage 1 T1D, a year of high-dose oral insulin did not change progression (40% in each group at 5 years) or immune response to insulin.
The stage 2 approval was widened from age 8 and older to age 1 and older, supported by the PETITE-T1D safety study.
In 188 children and adults with high HbA1c, the automated system lowered HbA1c by 0.8 points more than injections at 13 weeks, with no severe lows or DKA in either group.
The European Commission approved it to delay stage 3 T1D in people 8 and older with stage 2 T1D, the first disease-modifying T1D drug in the EU.
Insulin keeps people alive. Devices, an immune drug and islet cell therapies are changing what treatment looks like.
Replaces the hormone the body no longer makes. Most people with T1D need it every day to stay alive. Missing doses can lead to diabetic ketoacidosis, a life-threatening emergency.
The system adjusts insulin based on sensor readings. In the RADIANT trial (188 people aged 4 to 70), a tubeless system lowered average blood sugar (HbA1c) from 8.1% to 7.2% in 13 weeks, compared with 8.1% to 8.0% on injections. The trial was funded by the device maker.
An antibody given by IV for 12 to 14 days. It delays the onset of stage 3 T1D and slows the loss of the body's own insulin. It carries a boxed warning for serious viral reactivation (Epstein-Barr virus and cytomegalovirus).
Islet cells from deceased donors, infused into a liver vein. In two small studies, 21 of 30 people stopped insulin for at least a year. Patients must take immune-suppressing drugs, and some stopped because of serious side effects.
Islet cells grown from stem cells. In NEJM, 10 of 12 full-dose patients were off insulin at one year. Lifelong immune suppression is required, and two patients died during the study. Not approved.
Donor islet cells gene-edited to hide from the immune system. In one person, they kept making insulin for 14 months with no immune-suppressing drugs. This is a single patient, and much larger trials are needed.
| Treatment | For | What it does |
|---|---|---|
| Insulin (injections or pump) | Everyone with stage 3 T1D | Replaces missing insulin. Needed every day. |
| Automated insulin delivery | Many children and adults | Adjusts insulin automatically from glucose-sensor readings. |
| Teplizumab (Tzield) | Stage 2 (age 1+); recent stage 3 (ages 8–17, U.S.) | Delays diagnosis or slows the loss of the body's own insulin. Does not replace insulin after diagnosis. |
| Pramlintide (Symlin) | People on mealtime insulin who are not at goal | Add-on that helps control blood sugar after meals. Boxed warning for severe low blood sugar. |
| Donislecel (Lantidra) | Adults with repeated severe low blood sugar | Donor islet transplant. Requires immune-suppressing drugs. |
No supplement or diet replaces insulin in type 1 diabetes. Daily habits help manage blood sugar alongside insulin. We rate each by the strength of evidence.
Can help lower blood sugar, blood pressure and cholesterol. Ask your care team how to adjust insulin and food around exercise.
A plan built with a dietitian or diabetes educator helps match food and insulin.
Part of diabetes self-care, though trial evidence for better blood sugar is limited.
Studies are small and inconsistent, with no clear conclusions. None replaces insulin.
The FDA warns these are marketed illegally. Some are harmful, and all are harmful if used in place of real treatment.
Missing insulin can cause diabetic ketoacidosis (DKA), which is life-threatening.
Be careful: never stop or cut insulin to try a supplement, diet or "cure." In type 1 diabetes, going without insulin can cause diabetic ketoacidosis, a life-threatening emergency. Some supplements can also cause side effects, such as kidney damage. Tell your care team about anything you take.
Centers recognized for expertise in this condition, and communities of people living with it.
Cares for children and adults with T1D and runs an Early T1D Clinic. It was a site in the TN-10 teplizumab prevention trial and the PROTECT trial in newly diagnosed children.
A listed site in Vertex's zimislecel cell-therapy trial. The University of Miami was also a site in the TN-10 and PROTECT teplizumab trials.
A site in both the TN-10 and PROTECT teplizumab trials.
A listed site in the zimislecel cell-therapy trial and a site in the PROTECT teplizumab trial.
A listed site in the zimislecel cell-therapy trial.
A listed UK site in the zimislecel cell-therapy trial.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Living with T1D means decisions every day, and other people with T1D understand. Most of these are free.
Funds T1D research and offers local chapters, community events, a resource library and a clinical-trial finder.
Visit ↗A nonprofit with a community app, a program for newly diagnosed people and guides on daily life with T1D.
Visit ↗A community for young adults with diabetes, with an online chat, local meetups and college chapters.
Visit ↗An active discussion forum run by Diabetes UK where members share their own experiences.
Visit ↗Many private parent, teen and adult groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment, especially insulin doses, with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Insulin is the base of care everywhere. Teplizumab is now approved in the U.S., EU, UK, Canada and China for stage 2. We verified islet cell therapy approval only in the U.S., for a small group.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| InsulinAll stage 3 T1D | Used | Used | Used | Used | Used | Used | Used | Used | Used |
| Teplizumab (Tzield / Teizeild)Delay stage 3 in stage 2 | Approved 2022 | Approved 2026 | Approved 2025 | Approved 2025 | — | — | Approved 2025 | — | — |
| TeplizumabRecent stage 3, ages 8–17 | Approved 2026 | — | — | — | — | — | — | — | — |
| Donislecel (Lantidra)Donor islet cells | Approved 2023 | — | — | — | — | — | — | — | — |
| Pramlintide (Symlin)Add-on to mealtime insulin | Approved 2005 | — | — | — | — | — | — | — | — |
The zimislecel trial lists recruiting sites in Canada, France, Germany, Italy, the Netherlands, Norway, Saudi Arabia and the UK, as well as the U.S.
The first transplant of gene-edited islet cells without immune-suppressing drugs, with 14-month results published in NEJM in 2026.
A Phase 2 randomized study of teplizumab in Japanese people with stage 2 T1D. It is recruiting, with completion estimated for 2028.
T1D is an autoimmune disease: the immune system attacks and destroys the beta cells in the pancreas that make insulin. Experts now describe it in stages that start years before symptoms.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations help people with type 1 diabetes and their families pay for supplies and care. Funds are limited and rules vary, so contact each one directly.
An equipment grant toward insulin pumps and CGMs, and an emergency grant toward insulin, unexpected hospital bills and other urgent diabetes costs. It only pays costs directly tied to managing type 1 diabetes, not rent or food.
See the grants ↗Formerly the TKJD Foundation. Pays back some costs of CGMs, insulin pumps and pump supplies, test strips and meters, syringes and pen needles. No maximum or deadline is stated.
See the program ↗Covers the cost of insulin, supplies such as CGM sensors, test strips and glucagon, endocrinology visits, counseling and emergency help for families who need it most.
See the application ↗Gives diabetes supplies, help with travel and lodging for appointments, medical alert IDs and, when needed, one-time rent help to Barbara Davis Center patients in need. Ask through the clinic.
See the program ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
Not individually cited: the 1922 first use of insulin in Toronto, and the "Used" entries for insulin in the approvals table, which reflect established medical history and WHO's statement that type 1 diabetes requires daily insulin; insulin's approval in each country was not checked one by one. All "—" cells in the approvals table are unverified (teplizumab in Japan is in a Phase 2 trial; a Wikipedia mention of Australian and Swiss approval was not confirmed from the regulators). The EU, Canada and China teplizumab approvals rest on Sanofi's own releases. The FDA approved the age-1 expansion on April 20, 2026 per Drugs@FDA, though news reports gave April 22. The zimislecel timeline, the manufacturing pause and the VX-017 plans rest on Vertex's own releases, and Vertex has not given a new filing date. The Sana hypoimmune result is one patient; whether that person still needs insulin injections was not stated in the sources we read. The RADIANT trial was funded by Insulet, the device maker. "Sleep and stress care" is graded limited because NCCIH lists it as part of self-care but we found no strong trial evidence. Expert care centers: no single official U.S. designation for type 1 diabetes centers could be verified, so these are listed for their roles as sites in registered pivotal trials (TN-10, PROTECT, zimislecel), plus the Barbara Davis Center's own description of its T1D clinics. No Reddit community could be confirmed today (Reddit blocked automated checks), so none is listed. Financial help: checked October 6, 2026. TK.Type 1's site blocks automated checks and was read with a headless browser. None of these organizations states a maximum grant. No national medical-cost charity was found with an open type 1 diabetes fund (HealthWell lists only a closed type 2 fund), and diabetic alert dog programs were left out because they place dogs rather than pay costs.